Dusseldorf - Delayed Quote EUR

Theralase Technologies Inc. R (TTX.DU)

0.1010

-0.0030

(-2.88%)

As of 4:32:01 PM GMT+2. Market Open.

Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association

Toronto, Ontario--(Newsfile Corp. - May 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of small molecules and their formulations, able to be activated by light, radiation, sound and/or other drugs, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that its latest interim clinical data was recently pre

Newsfile yesterday

TLTFF
Theralase Discovers New Mechanism of Action of Lead Drug

Theralase(R) Has Discovered a New Mechanism of Action in Its War on Cancer; Specifically, Ruvidar's(TM) Ability to Inhibit DeUbiquitinating Enzymes, an Important Class of Enzymes Which Have Been Linked to Numerous Cancers and Neurogenerative Diseases Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sou

Newsfile 8 days ago

TLTFF
Theralase(R) Closes Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement offering

Newsfile 21 days ago

TLTFF
TSX Penny Stocks: 3 Picks With Market Caps Under CA$300M

The Canadian market, like its U.S. counterpart, is navigating a complex landscape of economic factors, including potential tariff impacts and inflationary pressures that could influence investor decisions. Amidst this backdrop, penny stocks—often representing smaller or emerging companies—offer unique opportunities for growth at attractive price points. While the term "penny stocks" might seem dated, these investments can still provide significant upside when backed by strong financial health...

Simply Wall St. 26 days ago

NFGC

GPHOF

TLTFF
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments

Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulati

Newsfile 26 days ago

TLTFF
Ruvidar Demonstrates 7 Year Complete Response

Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) Demonstrates 7 Year Complete Response Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended f

Newsfile 29 days ago

TLTFF
Ruvidar Effective in the Treatment of Herpes

Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, inten

Newsfile last month

TLTFF
Theralase Technologies Full Year 2024 Earnings: Beats Expectations

Theralase Technologies ( CVE:TLT ) Full Year 2024 Results Key Financial Results Revenue: CA$1.03m (down 3.4% from FY...

Simply Wall St. last month

TLTFF
Theralase(R) Releases 2024 Annual Financial Statements

Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's audited consolidated financial statements for the twelve-month period

Newsfile last month

TLTFF
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients

Parkinson's Patients Have Improved Motor and Non-Motor Function After Treatment with Theralase(R) Cool Laser Therapy Toronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, b

Newsfile last month

TLTFF
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma

Rutherrin(R), when combined with a common diabetic drug and radiation, was able to effectively destroy Non-Hodgkin's Lymphoma in an animal model. Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective d

Newsfile 2 months ago

TLTFF
Theralase(R) Demonstrates Effective Treatment of Herpes

Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, ...

ACCESS Newswire 2 months ago

TLTFF
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses

Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, ...

ACCESS Newswire 2 months ago

TLTFF
February 2025 TSX Penny Stocks To Watch

The Canadian market is currently navigating a period of economic uncertainty, with the Bank of Canada cutting rates due to potential U.S. tariffs and a recent contraction in GDP. Despite these challenges, the concept of penny stocks—often representing smaller or newer companies—remains relevant for investors seeking opportunities at lower price points. By focusing on those with strong financial fundamentals, penny stocks can offer hidden potential without many of the associated risks, making...

Simply Wall St. 2 months ago

MFGCF

CCARF

TLTFF
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting

Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, ...

ACCESS Newswire 3 months ago

TLTFF
TSX Penny Stocks To Watch: 3 Picks Under CA$200M Market Cap

As the Canadian market reflects on a strong 2024, marked by an 18% gain in the TSX and robust performances across sectors, investors are now navigating a landscape of mixed economic signals and policy uncertainties. Amidst this backdrop, smaller companies often referred to as penny stocks continue to attract attention for their potential value and growth opportunities. While the term "penny stocks" may seem outdated, these investments can offer surprising stability when backed by solid...

Simply Wall St. 3 months ago

GENGF

TLTFF

DCMDF
Theralase Technologies Second Quarter 2024 Earnings: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)

Theralase Technologies ( CVE:TLT ) Second Quarter 2024 Results Key Financial Results Revenue: CA$100.8k (down 54% from...

Simply Wall St. 8 months ago

TLTFF
Theralase(R) Release’s 2Q2024 Financial Statements

TORONTO, ON / ACCESSWIRE / August 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated ...

ACCESS Newswire 8 months ago

TLTFF
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / July 8, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo ...

ACCESS Newswire 9 months ago

TLTFF
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy

TORONTO, ON / ACCESSWIRE / June 20, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated ...

ACCESS Newswire 10 months ago

TLTFF

Performance Overview

Return	TTX.DU	S&P/TSX Composite index (^GSPTSE)
YTD	--	+1.13%
1-Year	-1.94%	+11.85%
3-Year	-50.00%	+20.67%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Theralase Technologies Inc. R (TTX.DU)

Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association

Theralase Discovers New Mechanism of Action of Lead Drug

Theralase(R) Closes Non-Brokered Private Placement

TSX Penny Stocks: 3 Picks With Market Caps Under CA$300M

Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments

Ruvidar Demonstrates 7 Year Complete Response

Ruvidar Effective in the Treatment of Herpes

Theralase Technologies Full Year 2024 Earnings: Beats Expectations

Theralase(R) Releases 2024 Annual Financial Statements

Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients

Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma

Theralase(R) Demonstrates Effective Treatment of Herpes

Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses

February 2025 TSX Penny Stocks To Watch

Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting

TSX Penny Stocks To Watch: 3 Picks Under CA$200M Market Cap

Theralase Technologies Second Quarter 2024 Earnings: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)

Theralase(R) Release’s 2Q2024 Financial Statements

Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement

Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy

Performance Overview